Outcome of renal tumors registered in Japan Wilms Tumor Study-2 (JWiTS-2): A report from the Japan Children's Cancer Group (JCCG)
Outcome of renal tumors registered in Japan Wilms Tumor Study-2 (JWiTS-2): A report from the Japan Children's Cancer Group (JCCG)
复制标题
DOI：
10.1002/pbc.27056
复制
发表时间：
2018-07-01
影响因子：
3.2
通讯作者：
Fukuzawa, Masahiro
中科院分区：
文献类型：
--
作者：
Koshinaga, Tsugumichi;Takimoto, Tetsuya;Fukuzawa, Masahiro
背景日本肾母细胞瘤研究 2 (JWiTS-2) 要求对所有病例登记进行中央病理学审查。该研究旨在比较参加 JWiTS-1 和 JWiTS-2 试验的单侧肾母细胞瘤患者的结果。 程序 JWiTS-2 试验（2006-2014）是一项前瞻性、单臂研究，要求强制向中心病理学提交组织学切片，而在 JWiTS-1 试验中，这种提交不是强制性的。对 JWiTS-1 试验（1996-2005）中病例的无复发生存率（RFS）和总生存率（OS）进行统计评估。结果在 277 名经中央病理审查系统诊断的原发性肾肿瘤入组患者中，其中 225 名单侧肾肿瘤患者接受了超过 9 年的随访。 Wilms 肿瘤 (n=178) 的 RFS 和 OS 分别为 90.4% (P=0.0003) 和 96.8% (P=0.054)，而 JWiTS-1 的 RFS 和 OS 分别为 74.9% 和 89.4%。 JWiTS-2中I-III期Wilms肿瘤的RFS率超过90%，尽管IV期Wilms肿瘤的结果明显较差（RFS：66.2%）（P=0.0094）。肾透明细胞肉瘤（CCSK；n=31）的 RFS 和 OS 分别为 82.4%（P=0.30）和 91.3%（P=0.42），而 JWiTS-1 为 68.8% 和 81.3%；肾横纹肌瘤（RTK；n=16）的 RFS 和 OS 分别为 18.8%（P=0.88）和分别为 25.0% (P=0.80)，而 JWiTS-1 为 23.5% 和 23.5%。结论与 JWiTS-1 相比，JWiTS-2 中 I-III 期 Wilms 肿瘤的 RFS 和 OS 得到改善，而 IV 期 Wilms 肿瘤、CCSK 和 RTK 的结果没有改善。
BackgroundJapan Wilms Tumor Study-2 (JWiTS-2) mandated central pathology review for all case registrations. The study aimed to compare the outcomes of patients with unilateral Wilms tumor enrolled on the JWiTS-1 and JWiTS-2 trials.ProcedureThe JWiTS-2 trial (2006-2014), a prospective, single-arm study, required compulsory submission of histologic slides to central pathology, while in the JWiTS-1 trial, such submission was not compulsory. Relapse-free survival (RFS) and overall survival (OS) versus cases in the JWiTS-1 trial (1996-2005) were statistically evaluated.ResultsOf 277 enrolled patients with primary renal tumors diagnosed by the central pathology review system, 225 patients with unilateral renal tumors were followed up over 9 years. The RFS and OS of Wilms tumor (n=178) were 90.4% (P=0.0003) and 96.8% (P=0.054), respectively, as compared to 74.9% and 89.4% in JWiTS-1. RFS rates of stages I-III Wilms tumor in JWiTS-2 were more than 90%, although the outcome of stage IV Wilms tumor was significantly poorer (RFS: 66.2%) (P=0.0094). RFS and OS of clear cell sarcoma of the kidney (CCSK; n=31) were 82.4% (P=0.30) and 91.3% (P=0.42), respectively, as compared to 68.8% and 81.3% in JWiTS-1, and those of rhabdoid tumor of the kidney (RTK; n=16) were 18.8% (P=0.88) and 25.0% (P=0.80), respectively, as compared to 23.5% and 23.5% in JWiTS-1.ConclusionsRFS and OS for stages I-III Wilms tumor were improved in JWiTS-2 compared to JWiTS-1, whereas outcomes for stage IV Wilms tumor, CCSK, and RTK did not improve.